Startups
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
The robust $77 million Series A was led by Octagon Capital and the leadership and research team behind the original Vedere Bio.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
The help wanted signs are up across the biopharma industry. Companies are opening and expanding facilities, which is good news for job seekers.
Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.
Significant contributions were made to the Series A by Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
Catch up on the investment news quickly with BioSpace’s brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.
Biotechnology firm Ginkgo Bioworks is going public via a merger with Soaring Eagle Acquisition Corp.
Appia is developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients.
PRESS RELEASES